Biomarkers may predict chronic urticaria resolutionChronic urticaria is associated with a low resolution rate, but researchers writing in JAMA point to biomarkers that may help predict the likelihood of resolution.
Practice gapsDermatologists often must weigh their desire for definitive data with the realities of caring for individual patients.
Off-label systemic immunomodulators useful for various indicationsAlthough many systemic immunomodulators are approved for psoriasis, their mechanisms of action suggest they have utility in indications ranging from atopic dermatitis (AD) to chronic urticaria. Understanding a systemic immunomodulator’s mechanism of action provides a theoretical basis for uses beyond its labeled indication.
Purple papules pop up after antibiotic courseThe mother of a 17-year-old boy frantically brings him to the office for evaluation of an itchy, burning rash that started on his hands 1 hour ago.
Aspirin may exacerbate childhood urticariaA new study suggests that hypersensitivity to aspirin may cause complications in some children with chronic spontaneous urticaria.
Asthma drug relieves chronic hivesThe asthma drug omalizumab may provide symptom relief to patients with chronic idiopathic urticaria, results of a recently published study suggest.
Backyard flora drive itch, irritationRegarding reactions to common plant sources of allergy and injury, prevention is generally key. Because media reports sometimes exaggerate or embellish the impact of insect and plant exposures, dermatologists should stand ready to provide accurate information.
High-dose vitamin D may alleviate urticariaHigh-dose vitamin D3 as an adjuvant therapy holds potential benefit for patients suffering from chronic urticaria, according to results of a recent study.
MauiDerm 2014 kicks off with therapeutic updates, industry advancesThe MauiDerm 2014 meeting kicked off Sunday with a Hawaiian blessing led by the conference's organizer, George Martin, M.D., Dermatology and Laser Center of Maui, Kihei, Hawaii.
FDA approves Xolair for chronic idiopathic urticariaThe Food and Drug Administration has approved Xolair (omalizumab, Novartis) for the treatment of chronic idiopathic urticaria in patients ages 12 and older.